INVO Bioscience, Inc. (INVO)
| Market Cap | 29.64M |
| Revenue (ttm) | 1.17M |
| Net Income (ttm) | -5.30M |
| Shares Out | 4.95M |
| EPS (ttm) | -0.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $3.11 |
| Previous Close | $3.13 |
| Change ($) | -0.02 |
| Change (%) | -0.64% |
| Day's Open | 3.10 |
| Day's Range | 3.02 - 3.12 |
| Day's Volume | 25,432 |
| 52-Week Range | 2.98 - 3.42 |
News
There are no news available yet.
About INVO
INVO Bioscience, a medical device company, provides assisted reproductive technology solutions worldwide. The company offers INVOcell, a patented intravaginal culture system used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development; and INVOcell Retention device, a single-use modified diaphragm that includes holes to allow for natural drainage of vaginal fluids to aid in retention of the INVOcell device in the vaginal cavity during the incubation period. It also provides fixed laboratory equipme... [Read more...]
| Industry Medical Devices | Founded 2007 |
| CEO Steven M. Shum | Employees 5 |
| Stock Exchange NASDAQ | Ticker Symbol INVO |
Financial Performance
In 2019, INVO's revenue was $1.48 million, an increase of 199.41% compared to the previous year's $494,375. Losses were -$2.17 million, -29.54% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for INVO stock is "Buy." The 12-month stock price forecast is 5.38, which is an increase of 73.27% from the latest price.